Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy
Copyright policy )Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy
The four human epidermal growth factor receptors (HER1-4) are involved in growth stimulation and may play a role in endocrine resistance. The receptors form dimers, leading to activation by mutual phosphorylation. Our purpose was to explore the role of the activated receptors (pHER1, pHER2, pHER3) in endocrine treated breast cancer in terms of co-expression and association with disease-free survival (DFS) in 1062 patients with ER-positive tumors. Furthermore, HER2 amplification was evaluated. We found positive associations between the phosphorylated receptors. pHER1 and pHER3 were co-expressed with one or two of the other activated receptors in 85% and 89% of tumors, respectively, whereas pHER2 was co-expressed with the other activated receptors in 54% of tumors. Except for HER2, which was associated with poor prognosis, none of the remaining markers were associated with DFS. However, frequent co-expression indicates a role of the other HER-family members in activation of HER2.
- Breast Cancer Over Time United States
- Herlev Hospital Denmark
- Danish Cancer Society Denmark
- Harvard University United States
- University of Copenhagen Denmark
Receptor, ErbB-2, ErbB-4, Tumor/metabolism, Phosphorylation, Hormonal/therapeutic use, Tumor Markers, Adjuvant, In Situ Hybridization, In Situ Hybridization, Fluorescence, Mastectomy, ErbB Receptors/metabolism, Nitriles/therapeutic use, ErbB-3/metabolism, Middle Aged, Immunohistochemistry, ErbB Receptors, Treatment Outcome, Tumor Markers, Biological, Chemotherapy, Adjuvant, Letrozole, ErbB-2/metabolism, Female, Triazoles/therapeutic use, Receptor, Receptor, erbB-2, Antineoplastic Agents, Hormonal, Receptor, erbB-3, Receptor Protein-Tyrosine Kinases/metabolism, Antineoplastic Agents, Breast Neoplasms, Fluorescence, Disease-Free Survival, Breast Neoplasms/drug therapy, Double-Blind Method, Nitriles, Biomarkers, Tumor, Chemotherapy, erbB-3, Humans, erbB-2, Aged, Hormonal, Epidermal Growth Factor, Receptor Protein-Tyrosine Kinases, Triazoles, Biological, Tamoxifen, Tamoxifen/therapeutic use, Receptor, Epidermal Growth Factor, Biomarkers, Follow-Up Studies
Receptor, ErbB-2, ErbB-4, Tumor/metabolism, Phosphorylation, Hormonal/therapeutic use, Tumor Markers, Adjuvant, In Situ Hybridization, In Situ Hybridization, Fluorescence, Mastectomy, ErbB Receptors/metabolism, Nitriles/therapeutic use, ErbB-3/metabolism, Middle Aged, Immunohistochemistry, ErbB Receptors, Treatment Outcome, Tumor Markers, Biological, Chemotherapy, Adjuvant, Letrozole, ErbB-2/metabolism, Female, Triazoles/therapeutic use, Receptor, Receptor, erbB-2, Antineoplastic Agents, Hormonal, Receptor, erbB-3, Receptor Protein-Tyrosine Kinases/metabolism, Antineoplastic Agents, Breast Neoplasms, Fluorescence, Disease-Free Survival, Breast Neoplasms/drug therapy, Double-Blind Method, Nitriles, Biomarkers, Tumor, Chemotherapy, erbB-3, Humans, erbB-2, Aged, Hormonal, Epidermal Growth Factor, Receptor Protein-Tyrosine Kinases, Triazoles, Biological, Tamoxifen, Tamoxifen/therapeutic use, Receptor, Epidermal Growth Factor, Biomarkers, Follow-Up Studies
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).7 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!